GAVI Meeting: Understanding the value of vaccines

Meeting: Understanding the value of vaccines
GAVI
Annecy, France
Week of 14 January 2013

GAVI said it convened a group of 25 health economists and other experts from around the world experts “to better understand the full value of vaccines,” and to agree on a programme of future research to answer some of the key questions raised. The GAVI announcement noted that “…as well as preventing death and illness, we know that vaccines make a broader contribution to human and economic development. Some of the ways in which this happens are already well understood: children who are healthy do not require medical treatment or care that costs money; their families are then able to spend or save this money in other ways…Other known and potential impacts require further research. For example: what is the link between vaccines, health and educational achievement? How can we measure the connection between childhood health and future economic prospects?”

http://www.gavialliance.org/library/news/gavi-features/2013/understanding-the-value-of-vaccines/

Editorial: What must be done about the killings of Pakistani healthcare workers?

British Medical Journal
19 January 2013 (Vol 346, Issue 7891)
http://www.bmj.com/content/346/7891

Editorial
What must be done about the killings of Pakistani healthcare workers?
Zulfiqar A Bhutta,
Founding Chair, Division of Women and Child Health, Aga Khan University, Karachi, Pakistan
BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f280 (Published 16 January 2013)

Extract
It’s time to stop trying to accommodate those who spread fear and terror

In December 2012 nine volunteer polio workers, six of whom were young women, were murdered in Pakistan.1 A day later five female education workers were murdered on their way to work in Swabi (Khyber Pakhtunkhwa). The coordinated attacks sent a chilling message to civic society that female workers and volunteers, hitherto protected by a strict Pashtun moral code, were now terrorist targets. These murders begin to fade into a background of incessant conflict and insurgency around the border areas of Khyber Pakhtunkhwa, the federally administered tribal areas, and Baluchistan. The city of Karachi is caught in a spiral of targeted killings and kidnappings for ransom.2 In Baluchistan, the law of the government has all but collapsed and the Hazara minorities have been forced to demand army rule in the main city, Quetta, to protect themselves from the threat of ethnic cleansing at the hands of a well connected and funded underground network of terrorist organisations.3 The nation is inured to reports of violent deaths on a daily basis, however, and the recent targeted killings of health workers are already off…

Evidence for use of pneumococcal conjugate vaccines

The Lancet  
Jan 19, 2013  Volume 381  Number 9862  p177 – 266  e1
http://www.thelancet.com/journals/lancet/issue/current

Comment
More evidence for use of pneumococcal conjugate vaccines
Cynthia G Whitney

Preview
Pneumococcal conjugate vaccines (PCVs) are among the leading interventions for reducing deaths and improving the health of children around the world. These vaccines are now routinely used in about 88 countries, with the number of countries increasing quickly.1 PCVs are used on various schedules, designed to complement existing schedules for other vaccines that are already part of national immunisation programmes. Until now, however, clinical trial evidence to support some of the different ways PCVs can be used was missing.

Articles
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial
Arto A Palmu, Jukka Jokinen, Dorota Borys, Heta Nieminen, Esa Ruokokoski, Lotta Siira, Taneli Puumalainen, Patricia Lommel, Marjan Hezareh, Marta Moreira, Lode Schuerman, Terhi M Kilpi
Preview | Summary

Risk of Fetal Death after Pandemic Influenza Virus Infection or Vaccination

New England Journal of Medicine
January 17, 2013  Vol. 368 No. 3
http://content.nejm.org/current.shtml

Online First – Original Article
Risk of Fetal Death after Pandemic Influenza Virus Infection or Vaccination
Siri E. Håberg, M.D., Ph.D., Lill Trogstad, M.D., Ph.D., Nina Gunnes, Ph.D., Allen J. Wilcox, M.D., Ph.D., Håkon K. Gjessing, Ph.D., Sven Ove Samuelsen, Ph.D., Anders Skrondal, Ph.D., Inger Cappelen, Ph.D., Anders Engeland, Ph.D., Preben Aavitsland, M.D., Steinar Madsen, M.D., Ingebjørg Buajordet, Ph.D., Kari Furu, Ph.D., Per Nafstad, M.D., Ph.D., Stein Emil Vollset, M.D., Dr.P.H., Berit Feiring, M.Sc.Pharm., Hanne Nøkleby, M.D., Per Magnus, M.D., Ph.D., and Camilla Stoltenberg, M.D., Ph.D.
January 16, 2013DOI: 10.1056/NEJMoa1207210
http://www.nejm.org/doi/full/10.1056/NEJMoa1207210

Abstract
Background
During the 2009 influenza A (H1N1) pandemic, pregnant women were at risk for severe influenza illness. This concern was complicated by questions about vaccine safety in pregnant women that were raised by anecdotal reports of fetal deaths after vaccination.
Full Text of Background…

Methods
We explored the safety of influenza vaccination of pregnant women by linking Norwegian national registries and medical consultation data to determine influenza diagnosis, vaccination status, birth outcomes, and background information for pregnant women before, during, and after the pandemic. We used Cox regression models to estimate hazard ratios for fetal death, with the gestational day as the time metric and vaccination and pandemic exposure as time-dependent exposure variables.
Full Text of Methods…

Results
There were 117,347 eligible pregnancies in Norway from 2009 through 2010. Fetal mortality was 4.9 deaths per 1000 births. During the pandemic, 54% of pregnant women in their second or third trimester were vaccinated. Vaccination during pregnancy substantially reduced the risk of an influenza diagnosis (adjusted hazard ratio, 0.30; 95% confidence interval [CI], 0.25 to 0.34). Among pregnant women with a clinical diagnosis of influenza, the risk of fetal death was increased (adjusted hazard ratio, 1.91; 95% CI, 1.07 to 3.41). The risk of fetal death was reduced with vaccination during pregnancy, although this reduction was not significant (adjusted hazard ratio, 0.88; 95% CI, 0.66 to 1.17).
Full Text of Results…

Conclusions
Pandemic influenza virus infection in pregnancy was associated with an increased risk of fetal death. Vaccination during pregnancy reduced the risk of an influenza diagnosis. Vaccination itself was not associated with increased fetal mortality and may have reduced the risk of influenza-related fetal death during the pandemic. (Funded by the Norwegian Institute of Public Health.)
Full Text of Discussion…

Killings Force Rethinking of Pakistan’s Anti-Polio Drive

Science        
18 January 2013 vol 339, issue 6117, pages 245-364
http://www.sciencemag.org/current.dtl

News & Analysis
Disease Eradication
Killings Force Rethinking of Pakistan’s Anti-Polio Drive
Leslie Roberts

Pakistan is one of just three countries where the poliovirus remains entrenched, and global cases are at an all-time low. Over the years, polio workers have been killed in conflict zones, but never in such numbers or in such deliberate attacks as in Pakistan. Health workers are asking, can the government safeguard its legions of vaccinators and still reach enough kids to keep the poliovirus in check? And if not and the virus regains steam, how big of a setback will that be to the global initiative, which, 13 years after it was due to be finished, is finally close to success?

http://www.sciencemag.org/content/339/6117/259.summary

“1-2-3 Pap” Intervention Improves HPV Vaccine Series Completion Among Appalachian Women

Journal of Communication
Early View – ORIGINAL ARTICLE

“1-2-3 Pap” Intervention Improves HPV Vaccine Series Completion Among Appalachian Women
Robin C. Vanderpool1,*, Elisia Cohen2, Richard A. Crosby1, Maudella G. Jones3, Wallace Bates3, Baretta R. Casey1, Tom Collins3
Article first published online: 10 JAN 2013
DOI: 10.1111/jcom.12001
http://onlinelibrary.wiley.com/doi/10.1111/jcom.12001/abstract?deniedAccessCustomisedMessage=&userIsAuthenticated=false

Abstract
Completion of the Human Papillomavirus (HPV) vaccine series is a national priority. This study not only identified correlates of intent to complete the vaccine series and actual series completion, but also tested the efficacy of a DVD intervention to promote series completion. Women’s beliefs that all 3 doses reduced cancer risk predicted intent and completion. Intention predicted completion, as did the belief that having a friend accompany the woman would promote completion. Beyond these effects, women assigned to the intervention were 2.44 times more likely than women in the usual care group to complete the series. Thus, in controlled analyses, a theory-grounded DVD intervention successfully promoted HPV series completion in a community setting. This method of intervention has high translational potential.

Cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.

Cancer Causes & Control
2013 Jan 5. [Epub ahead of print]
Prevalence of HPV types in cervical specimens from an integrated healthcare delivery system: baseline assessment to measure HPV vaccine impact.

Dunne EF, Klein NP, Naleway AL, Baxter R, Weinmann S, Riedlinger K, Fetterman B, Steinau M, Scarbrough MZ, Gee J, Markowitz LE, Unger ER.

http://www.ncbi.nlm.nih.gov/pubmed/23292130

Abstract
PURPOSE:
Two human papillomavirus (HPV) vaccines are available to prevent cervical cancer. One early measure of HPV vaccine impact would be a reduction in vaccine-related HPV types (HPV 6, 11, 16, or 18, or HPV 16, 18) in cervical samples from young women. We aimed to assess feasibility of specimen collection and baseline HPV prevalence in an integrated healthcare delivery system.

METHODS:
Residual cervical specimens collected during routine cervical cancer screening (2006-2008) were retained consecutively from eligible females aged 11-29 years, stratified by age group. Specimens were evaluated for 37 HPV genotypes using the Roche Linear Array assay.

RESULTS:
Of 10,124 specimens submitted, 10,103 (99 %) were adequate for HPV testing. Prevalence of HPV 6, 11, 16, or 18 genotype was 11.4 % overall and was the highest in the youngest age group (18.1 % in the 11-19-year-olds, 12.5 % in the 20-24-year-olds, and 7.0 % in the 25-29-year-olds).

CONCLUSIONS:
HPV types 6, 11, 16, or 18 prevalence could be measured over time to assess early HPV vaccine impact using residual specimens from an integrated healthcare delivery system, particularly if sampling focused on young women.

Op-Ed: “Stick With the Science” [thiomersal]

New York Times
http://www.nytimes.com/
Accessed 19 January 2013.

Op-Ed Contributor
Stick With the Science
By SETH BERKLEY
Published: January 17, 2013

GOVERNMENT representatives are meeting in Geneva this week to decide whether to introduce a global ban on mercury that could include thiomersal, a mercury-based preservative that has been used in some vaccine manufacturing since the 1930s to prevent bacterial or fungal contamination of multidose vials of vaccine.

Hosted by the United Nations Environment Program, the intergovernmental negotiating committee is charged with drafting a global treaty to rid the world of the threats posed by mercury.

Despite the ominous connotations of mercury, the decision should in theory be a no-brainer: The scientific and medical consensus is that thiomersal poses no human health risk, and that rather than saving lives, a ban would put millions of the world’s poorest children at risk of deadly diseases by disrupting vaccination programs.

But with vaccines, logic and evidence don’t always prevail. In the late 1990s we were at a similar juncture when, as part of a broader remit to find ways to reduce the human health hazards posed by mercury and under pressure from anti-vaccine lobbyists, the U.S. Food and Drug Administration turned its attention to the safety of thiomersal (known in the U.S. as thimerosal).

Despite a lack of evidence that it was harmful — and in the absence of any evidence to show that it wasn’t — the F.D.A. decided to take a precautionary approach and urged manufacturers to reduce or eliminate thiomersal from almost all vaccines in the United States.

Since then, scientists have published unequivocal evidence of its safety, including a 2006 study which showed that thiomersal is broken down by the body into ethylmercury. Unlike methylmercury, say from contaminated fish, which can make its way through the food chain and accumulate in the body, ethylmercury is naturally flushed out of the body within a couple of weeks. Despite such clinical and laboratory evidence, the damage to thiomersal’s reputation had already been done, and anti-vaccine campaigners are still trying to fan the flames.

Anti-vaccination groups have long campaigned against the use of thiomersal, claiming that this organic mercury derivative was responsible for increases in developmental disorders such as autism. What’s more, they argue that with a precautionary reduction already in place in the United States, denying children in developing countries access to the same thiomersal-free vaccines would be a global injustice.

Nothing could be further from the truth. Quite apart from the mountain of scientific evidence refuting any link between thiomersal and autism, with some studies involving hundreds of thousands of children [pdf], banning thiomersal or phasing out this agent would have a devastating impact on global health and lead to millions of children being denied access to life-saving vaccines.

To some extent, thiomersal is still used in vaccines in the United States and Europe, for example in some flu shots, but if there were a ban we could easily switch to single-dose vials.

In developing countries this is not so simple. Not only are single-dose vials less cost effective and less practical for mass vaccinations, they also take up more space in refrigerators, which are already at peak storage capacity. In the absence of any alternative preservative, far fewer vaccines would reach children in developing countries.

This would be a tragedy. In 2010 alone it is estimated that more than 1.4 million child deaths were prevented through the use of thiomersal-containing vaccines. Little wonder that organizations such as the World Health Organization, Doctors Without Borders, the American Academy of Pediatrics, the U.S. Institute of Medicine and the GAVI Alliance oppose a ban.

Indeed thiomersal is not the main target of the anti-mercury treaty, but rather an unfortunate bycatch. Even so, in many ways the situation mirrors the debate that took place more than a decade ago. This time it is the U.N.E.P. that is undertaking the laudable task of reducing the human health impact of mercury. The problem is that under pressure from anti-vaccine groups, hard scientific evidence is sometimes disregarded.

A recent example of this took place in December in a French case involving a claim by a former state employee that the aluminum content of vaccines given to him at work made him chronically ill. Although the court was not convinced of a probable link between the man’s illness and vaccinations, and in the absence of any scientific evidence of a link or any other explanation, it ruled in favor of the employee.

That is not to say that taking precautions isn’t intrinsically sensible; it’s just that sometimes dodging the issue in this way is not the best precaution, and instead of solving problems it sometimes creates them.

One of the core principles of medicine is “primum non nocere”: first, do no harm. But given the sheer numbers of lives at stake there is a strong argument that the burden of proof be shifted to the detractors.

Where a vaccine already has an established and strong safety record and is saving lives, the onus should be on producing evidence of a genuine risk before there is any change in policy related to its availability.

With millions of vulnerable lives at stake, the treaty negotiators need to engage and recognize that a ban on thiomersal would be bad policy based on bad science.

Seth Berkley is a medical epidemiologist and chief executive of the GAVI Alliance, a public-private global health partnership to increase access to immunization in poor countries.

Twitter Watch (19 January 2013 – 19:43)

Twitter Watch (19 January 2013 – 19:43)
Items of interest from a variety of twitter feeds associated with immunization, vaccines and global public health. This capture is highly selective and is by no means intended to be exhaustive.

World Bank Data @worldbankdata
We’ve just updated the World Development Indicators – get the most current and accurate global development #opendata – http://cot.ag/X8snXG 
Retweeted by World Bank
12:28 PM – 18 Jan 13

CDC Flu ‏@CDCFlu
Today, CDC announced 48 states have reported widespread flu activity. http://1.usa.gov/gUUlCT . Get a flu vax to protect yourself from flu.
Retweeted by CDCgov
9:28 AM – 18 Jan 13

IHME at UW ‏@IHME_UW
RT @fogarty_nih: Recorded webcast of Dr Chris Murray of IHME @UW speaking yesterday at #NIH on #GBD2010 is now live > http://videocast.nih.gov/Summary.asp?File=17753 …
9:32 AM – 18 Jan 13

GAVI Alliance ‏@GAVIAlliance
Next week, GAVI CEO @GAVISeth & GAVI Board Chair @Hoybraten will attend #WEF Annual Meeting in #Davos! Follow them! http://ht.ly/gVb8f 
2:49 AM – 18 Jan 13

WHO @WHO
An estimated 20 million children worldwide did not receive the first dose of #measles vaccine in 2011
12:08 PM – 17 Jan 13

WHO ‏@WHO
In 2011, large #measles outbreaks were reported, among others, in DRC, Ethiopia, India, Nigeria, Pakistan, France, Italy, Spain
11:32 AM – 17 Jan 13

Vaccines:The Week in Review 12 January 2013

Editor’s Notes:

Email Summary: Vaccines: The Week in Review is available as a weekly email summary: please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_12 January 2013_PDF

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.

Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…

NFID to honor Paul Offit with the Maxwell Finland Award for Scientific Achievement

The National Foundation for Infectious Diseases (NFID) announced that it will honor Dr. Paul A. Offit with the Maxwell Finland Award for Scientific Achievement at its Annual Awards Dinner on Tuesday, March 5, 2013. The award will be presented to Dr. Offit “for his outstanding work in the pediatric vaccine arena and his ongoing commitment to vaccine advocacy.” The Award is given to a scientist who has made outstanding contributions to the understanding of infectious diseases or public health. The announcement noted that ”Dr. Paul A. Offit is an impassioned advocate for immunization. He has rallied the scientific counterattack against the anti-vaccine movement. Dr. Offit is the co-inventor of the RotaTeg rotavirus vaccine which is recommended for universal use in infants in the US and is widely used in other countries. Dr. Offit is credited with saving countless lives worldwide.”

Vijay Samant, president and chief executive officer of Vical, Inc., commented “I believe Dr. Offit is a most appropriate candidate for the Maxwell Finland Awards for his broad influence on the pediatric vaccine field, from his development of the life-saving rotavirus vaccines, to his exemplary pediatric practice, to his staunch support of childhood immunization against zealous opponents. His insightful and approachable style of writing has helped bridge the gap between medical research and the general public. His legacy must include both the hundreds of thousands of lives already saved by the rotavirus vaccines, and the million more that will be saved by his advocacy for prudent vaccine policy.”

http://www.nfid.org/publications/helix/December-2012.pdf

Pfizer: European Commission approves expanded use of Prevenar 13

Pfizer announced that the European Commission has approved expanding the use of Prevenar 13 to older children and adolescents aged 6 to 17 years for active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by vaccine-type Streptococcus pneumoniae. Children in this age group who have not previously received Prevenar 13 may receive a single dose of the vaccine.

http://www.businesswire.com/news/home/20130108005435/en/Pfizer-Receives-European-Approval-Expand-Prevenar-13

PATH MVI and Inovio announce follow-on collaboration

The PATH Malaria Vaccine Initiative (MVI) and Inovio Pharmaceuticals, Inc. announced a follow-on collaboration to advance malaria vaccine development and new vaccination delivery technologies. Researchers “will test whether a novel vaccine approach that combines genetically engineered DNA with an innovative vaccine delivery technology called electroporation could induce an immune response in humans that protects against malaria parasite infection.” This follow-on agreement for clinical development builds on a 2010 research and development collaboration between Inovio and MVI.  Electroporation “deploys controlled electrical impulses to create temporary pores in a cell membrane, allowing uptake of the synthetic DNA. The cell then uses the DNA’s instructions to produce proteins that mimic the presence of the malaria pathogen, with the aim of inducing an immune response that provides protection against malaria.” Dr. David C. Kaslow , director of MVI, said, “We are excited to bring this innovative delivery technology into clinical testing to see whether the compelling immune responses seen in animal models translate to humans. Determining if and how these potent immune responses lead to protection against infection with the most deadly form of malaria is a high priority in our efforts to develop a next generation malaria vaccine.”

http://www.prnewswire.com/news-releases/path-malaria-vaccine-initiative-and-inovio-pharmaceuticals-partner-to-accelerate-development-of-malaria-vaccines-and-innovative-delivery-technologies-185835962.html

GAVI – first ever review by MOPAN

GAVI said it welcomed results from its first ever review by MOPAN (Multilateral Organisation Performance Assessment Network) in which it was “…commended for its effectiveness in increasing access to immunisation and for its focus on results.” GAVI said the review noted strengths including financial management, accountability checks, country ownership support and relationship management, and that it “was rated adequate, strong or above for 95% of the key performance indicators as a result of the document review.” The review also highlighted areas where performance could be improved, such as iGAVI’s “strategic management, its use of indicators to measure progress towards Paris Declaration Commitments, the management practices used in its budgeting process and its guidelines on evaluation coverage.” MOPAN is a network of 17 donor countries, representing the majority of worldwide Overseas Development Assistance (ODA), which rates the effectiveness of multilateral organisations. MOPAN members share information, carry out joint assessments and draw on each other’s expertise in evaluation. This review was led by the governments of France, Spain and Sweden. To serve as a basis for the report, country-level surveys were undertaken in 15 GAVI-eligible countries, including Bangladesh, Cambodia, the Democratic Republic of the Congo, Georgia, Ghana, Honduras, Indonesia, Nicaragua, Niger, Nigeria, Pakistan, Rwanda, the United Republic of Tanzania, the Republic of Yemen and Zimbabwe. http://www.gavialliance.org/library/news/statements/2013/gavi-recognised-for-effectiveness-and-focus-on-results/

IFFIm elects three board memebrs

IFFIm (International Finance Facility for Immunisation) announced that “three longtime banking officials with significant international experience joined its board of directors on 1 January 2013. The 3-year terms were approved by the board in December and include:

– Cyrus Ardalan, Vice Chairman of Barclays, where he has served in several key roles in government relations, emerging markets and investment banking…

– Marcus Fedder, who most recently has focused on microfinance after a long career in banking, during which he held senior positions at Toronto Dominion Bank, CIBC and Deutsche Bank…

Christopher Egerton-Warburton, who helped create IFFIm as the lead banker at Goldman Sachs at its creation…

The appointments are in conjunction with the expiring term of John Cummins, who rotated off the board at year-end 2012, the upcoming expiration of the term of Dayanath Jayasuriya at end-June 2013, and the departure of Arunma Oteh at year-end 2011. “IFFIm is a multilateral development institution created to accelerate the availability of predictable, long-term funds for health and immunisation programmes through the GAVI Alliance in more than 50 of the world’s poorest countries. It has raised more than US$ 3.7 billion in the bond markets, backed by US$ 6.3 billion in pledges from nine countries.”

http://www.iffim.org/library/news/press-releases/2013/iffim-appoints-three-new-members-to-its-board-of-directors/

GPEI: Update: Polio this week – As of 09 January 2013

Update: Polio this week – As of 09 January 2013
Global Polio Eradication Initiative
http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx

[Editor’s Extract and bolded text]
– Two years polio-free: January 13 will mark two years since a child was paralyzed by wild poliovirus in India, a country once considered the most complex challenge to global polio eradication.
– Response to Niger outbreak: The first immunization activities start in Niger on 112 January 2013, in close coordination with Nigeria. This first outbreak of imported wild poliovirus in 2012 is due to virus of Nigerian origin.

Afghanistan
– Two new WPV cases were reported in the past week, bringing the total number of WPV cases for 2012 to 37. Both of the WPV cases occurred in Nangarhar (2 WPV1), a newly infected province, with onset of paralysis on 20 December 2012. Outbreak response immunization in 10 districts in Nangarhar will be conducted using bivalent OPV.
– No new cases of circulating vaccine-derived poliovirus type (cVDPV) were reported in the past week. The total number of cVDPV cases for 2012 remains 4.

Nigeria
– Two new WPV cases were reported in the past week (1 WPV1 from Kano and 1 WPV1 from Katsina), bringing the total number of WPV cases for 2012 to 121. The most recent case occurred in Federally Capital Territory and had onset of paralysis on 3 December 2012. Both of the cases reported this week occurred in previously-infected districts.
– Two new cVDPV2 cases were reported in the past week, bringing the total number of cVDPV2 cases for 2012 to 6. Both cases occurred in Kebbi (Koko/Besse district), a province that had not previously reported any cases of cVDPV in 2012. The most recent had onset of paralysis on 24 November 2012.
– Given the spread of WPV of Nigerian origin to Niger, targeted Supplementary Immunization Activities will take place in high-risk and under-served districts in Nigeria on 12-112 January and in the wards of Sokoto, Katsina and Zamfara states bordering Niger on 15-18 January, synchronized with Niger.
– Staggered National Immunization Days across Nigeria are planned for 26 Jan – 2 February and 23 Feb – 2 March, also to be synchronized with Niger.

Niger
– Niger reports polio: In the first outbreak of polio in 2012 outside of an endemic country or a country with re-established poliovirus, Niger has reported a case of wild poliovirus. This is the first case in the country since December 2011 and is related to virus originating in Nigeria.

WHO: WER; GAR; Humanitarian Health Action [12 Jan 2013]

The Weekly Epidemiological Record (WER) for 11 January 2013, vol. 88, 2 (pp 17–28) includes:
– Monitoring and evaluation of preventive chemotherapy
– Estimated number of people covered by preventive chemotherapy: update for 2010 and 2011
http://www.who.int/entity/wer/2013/wer8802.pdf

WHO – Global Alert and Response (GAR)
Disease Outbreak News – Most recent news items
12 December 2012
Yellow fever in the Republic of Congo
6 December 2012
Yellow fever in Sudan – update

 
WHO – Humanitarian Health Action
No new reports
http://www.who.int/hac/en/index.html

Save the Children releases new report – Ending Poverty in Our Generation

Save the Children released a new report –  Ending Poverty in Our Generation – which outlines a new development system it said could “end extreme poverty in the next 20 years,” and includes “one of the first proposals for new targets to replace the Millennium Development Goals.” Save the Children’s CEO Carolyn Miles said, “With the 2015 deadline fast approaching, Save the Children is working globally to ensure that collectively, we learn the lessons of the current Millennium Development Goals and contribute to the evolution of an ambitious new global development framework. Our flagship report discusses what we believe are core priorities and identifies 10 key recommendations for fostering a post-2015 framework that emphasizes human development, equity, and accountability with a focus on our future – the children.”.”
http://www.savethechildren.org/site/apps/nlnet/content2.aspx?c=8rKLIXMGIpI4E&b=8486805&ct=12713395&notoc=1

[Editor’s Note: We extract a short portion of the Executive Summary below.]
“Save the Children’s suggested post-2015 development framework champions universal and equitable development, with human rights as its guiding principle and evidence as a foundation for its approaches.

“Human rights principles such as universality, equality and inalienability must underpin everything that is agreed. And, unlike with the MDGs, these principles must be visible in the targets established. Now is the time to aim at no less than:
– a zero target for absolute poverty reduction

– a zero target for hunger

– a zero target for preventable child and maternal deaths

– a zero target for those without safe drinking water and sanitation…

…We propose the following six goals for the new framework, to put in place the foundations for human development:
– Goal 1: By 2030 we will eradicate extreme poverty and reduce relative poverty through inclusive growth and decent work

– Goal 2: By 2030 we will eradicate hunger, halve stunting, and ensure universal access to sustainable food, water and sanitation

– Goal 3: By 2030 we will end preventable child and maternal mortality and provide basic healthcare for all

– Goal 4: By 2030 we will ensure children everywhere receive quality education and have good learning outcomes

– Goal 5: By 2030 we will ensure all children live a life free from all forms of violence, are protected in conflict and thrive in a safe family environment

– Goal 6: By 2030 governance will be more open, accountable and inclusive

To provide a supportive environment for these goals we propose four more:
– Goal 7: By 2030 we will establish effective global partnerships for development

– Goal 8: By 2030 we will build disaster-resilient societies

– Goal 9: By 2030 we will ensure a sustainable, healthy and resilient environment for all

– Goal 10: By 2030 we will deliver sustainable energy to all

http://www.savethechildren.org/atf/cf/%7B9def2ebe-10ae-432c-9bd0-df91d2eba74a%7D/ENDING_POVERTY_IN_OUR_GENERATION_AFRICA_LOW_RES_US_VERSION.PDF

[Editor’s Note 2: A search of the report using the terms “vaccine” and “immunization” yielded one occurrence on P.31 in the discussion of potential indicators for Goal 3]

– Goal 3: By 2030 we will end preventable child and maternal mortality and provide healthcare for all
Potential Indicators: 2j Percentage of infants aged 12–23 months who received three doses of diphtheria, pertussis and tetanus vaccine
Statement: UNICEF
UNICEF said it welcomed the launch of the Save the Children report, noting it as an “important contribution to discussions on the critical question of how the world can best address the survival, development and protection of its children in the coming years and decades, as part of an overall framework for sustainable and effective development.”  UNICEF noted that the report “..provides concrete ideas on setting new goals that will accelerate efforts for the progress and protection of the world’s most marginalized children. Valuably, it also addresses the question of how the most deep-seated challenges for children and families – such as inequalities, environmental fragility, weak accountability, natural disasters and conflict – can be better targeted in the present and coming generations.” http://www.unicef.org/media/media_67149.html

WHO: Global Maternal Health Conference

WHO: Global Maternal Health Conference
15–17 January 2013
Arusha, Tanzania
The Global Maternal Health Conference is a technical conference for scientists, researchers, and policy-makers to network, share knowledge, and build on progress toward eradicating preventable maternal mortality and morbidity by improving quality of care.

The 2013 conference will build on the successful technical focus and abstract-driven structure of the 2010 conference. There will be 5 conference tracks:
– Programme approaches and tools to improve the quality of maternal health care.
– Measurement of the quality of maternal health care.
– Strengthening health systems for improving the quality of maternal health care.
– Access to and utilization of quality maternal health care.
– Evidence-informed policy and advocacy for quality maternal health care.

http://www.who.int/mediacentre/events/meetings/2013/maternal_health_conference/en/index.html

WHO: Technical consultative meeting on novel human coronavirus

WHO: Technical consultative meeting on novel human coronavirus
14–15 January 2013
Cairo

9 January 2013 – To date, a total of nine laboratory-confirmed cases of infection with the novel human coronavirus have been reported to WHO – five cases, including three deaths, from Saudi Arabia, two cases from Qatar and two cases (both fatal) from Jordan.

The novel coronavirus first raised concerns in September 2012 when it caused severe respiratory disease in two patients from the Region. The subsequent discovery of two clusters of cases, one in a family in Saudi Arabia and the second in a group of health care workers in Jordan, increased the urgency of better understanding the virus. The potential of the virus to cause widespread serious consequences is thought to be significant, yet current knowledge of its epidemiology and natural history of infection with this agent is limited. Many critical questions about the source of the virus, its potential for transmission, important exposures and the clinical appearance of disease remain unanswered.

Many activities have already been conducted in investigating the new virus and managing its public health consequences. Within this context, WHO has organized a technical consultative meeting to take place at the WHO Regional Office in Cairo from 14 to 112 January 2013 on the novel human coronavirus. The meeting will bring together representatives of the three countries already affected, in addition to key partners and WHO collaborating centres involved in managing this public health issue, together with WHO experts…

http://www.emro.who.int/media/news/coronavirus-consultative-meeting.html

Effects of Socioeconomic Status and Health Care Access on Low Levels of HPV Vaccination Among Spanish-Speaking Hispanics in California

American Journal of Public Health
Volume 103, Issue 2 (February 2013)
http://ajph.aphapublications.org/toc/ajph/current

Effects of Socioeconomic Status and Health Care Access on Low Levels of Human Papillomavirus Vaccination Among Spanish-Speaking Hispanics in California
Shingisai Chando, Jasmin A. Tiro, T. Robert Harris, Sarah Kobrin, Nancy Breen
American Journal of Public Health: February 2013, Vol. 103, No. 2: 270–272.

ABSTRACT
Little is known about the effect of language preference, socioeconomic status, and health care access on human papillomavirus (HPV) vaccination. We examined these factors in Hispanic parents of daughters aged 11 to 17 years in California (n=1090). Spanish-speaking parents were less likely to have their daughters vaccinated than were English speakers (odds ratio [OR] = 0.55; 95% confidence interval [CI] =  0.31, 0.98). Adding income and access to multivariate analyses made language nonsignificant (OR = 0.68; 95% CI = 0.35, 1.29). This confirms that health care use is associated with language via income and access. Low-income Hispanics, who lack access, need information about free HPV vaccination programs.

http://ajph.aphapublications.org/doi/abs/10.2105/AJPH.2012.300920

Applying the GRADE approach to public health interventions: an empirical study

BMC Public Health
(Accessed 12 January 2013)
http://www.biomedcentral.com/bmcpublichealth/content

Research article  
Current experience with applying the GRADE approach to public health interventions: an empirical study
Eva A Rehfuess, Elie A Akl
BMC Public Health 2013, 13:9 (8 January 2013)
http://www.biomedcentral.com/1471-2458/13/9/abstract

Abstract (provisional)
Background
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach has been adopted by many national and international organisations as a systematic and transparent framework for evidence-based guideline development. With reference to an ongoing debate in the literature and within public health organisations, this study reviews current experience with the GRADE approach in rating the quality of evidence in the field of public health and identifies challenges encountered.

Methods
We conducted semi-structured interviews with individuals/groups that have applied the GRADE approach in the context of systematic reviews or guidelines in the field of public health, as well as with representatives of groups or organisations that actively decided against its use. We initially contacted potential participants by email. Responses were obtained by telephone interview or email, and written interview summaries were validated with participants. We analysed data across individual interviews to distil common themes and challenges.

Results
Based on 25 responses, we undertook 18 interviews and obtained 15 in-depth responses relating to specific systematic reviews or guideline projects; a majority of the latter were contributed by groups within the World Health Organization. All respondents that have used the GRADE approach appreciated the systematic and transparent process of assessing the quality of the evidence. However, respondents reported a range of minor and major challenges relating to complexity of public health interventions, choice of outcomes and outcome measures, ability to discriminate between different types of observational studies, use of non-epidemiological evidence, GRADE terminology and the GRADE and guideline development process. Respondents’ suggestions to make the approach more applicable to public health interventions included revisiting terminology, offering better guidance on how to apply GRADE to complex interventions and making modifications to the current grading scheme.

Conclusions
Our findings suggest that GRADE principles are applicable to public health and well-received but also highlight common challenges. They provide a starting point for exploring options for improvements and, where applicable, testing these across different types of public health interventions. Several public health organisations are currently testing GRADE, and the GRADE Working Group is eager to engage with these groups to find ways to address concerns.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Reforming antiretroviral price negotiations and public procurement: the Mexican experience

Health Policy and Planning
Volume 28 Issue 1 January 2013
http://heapol.oxfordjournals.org/content/current

Original articles
Reforming antiretroviral price negotiations and public procurement: the Mexican experience
Health Policy Plan. (2013) 28(1): 1-10 doi:10.1093/heapol/czs015

Abstract
Since antiretroviral (ARV) medicines represent one of the most costly components of therapy for HIV in middle-income countries, ensuring their efficient procurement is highly relevant. In 2008, Mexico created a national commission for the negotiation of ARV prices to achieve price reductions for their public HIV treatment programmes. The objective of this study is to assess the immediate impact of the creation of the Mexican Commission for Price Negotiation on ARV prices and expenditures.

A longitudinal retrospective analysis of procurement prices, volumes and type of the most commonly prescribed ARVs procured by the two largest providers of HIV/AIDS care in Mexico between 2004 and 2009 was carried out. These analyses were combined with 26 semi-structured key informant interviews to identify changes in the procurement process.

Prices for ARVs dropped by an average of 38% after the first round of negotiations, indicating that the Commission was successful in price negotiations. However, when compared with other upper-middle-income countries, Mexico continues to pay an average of six times more for ARVs.

The Commission’s negotiations were successful in achieving lower ARV prices. However, price reduction in upper-middle-income countries suggests that the price decrease in Mexico cannot be entirely attributed to the Commission’s first round of negotiations. In addition, key informants identified inefficiencies in the forecasting and procurement processes possibly affecting the efficiency of the negotiation process. A comprehensive approach to improving efficiency in the purchasing and delivery of ARVs is necessary, including a better clarification in the roles and responsibilities of the Commission, improving supply data collection and integration in forecasting and procurement, and the creation of a support system to monitor and provide feedback on patient ARV use.

http://heapol.oxfordjournals.org/content/28/1/1.abstract

GIVS: a mid-term analysis of progress in 50 countries

Health Policy and Planning
Volume 28 Issue 1 January 2013
http://heapol.oxfordjournals.org/content/current

Global Immunization Vision and Strategy (GIVS): a mid-term analysis of progress in 50 countries
Health Policy Plan. (2013) 28(1): 11-19 doi:10.1093/heapol/czs020
Lidija Kamara, Patrick Lydon, Julian Bilous, Jos Vandelaer, Rudi Eggers, Marta Gacic-Dobo, William Meaney, and Jean-Marie Okwo-Bele

Abstract
Within the overall framework set out in the Global Immunization Vision and Strategy (GIVS) for the period 2006–2015, over 70 countries had developed comprehensive Multi-Year Plans (cMYPs) by 2008, outlining their plans for implementing the GIVS strategies and for attaining the GIVS Goals at the midpoint in 2010 or earlier. These goals are to: (1) reach ≥90% and ≥80% vaccination coverage at national and district level, respectively; and (2) reduce measles-related mortality by 90% compared with the 2000 level. Fifty cMYPs were analysed along the four strategic areas of the GIVS: (1) protecting more people in a changing world; (2) introducing new vaccines and technologies; (3) integrating immunization, other health interventions and surveillance in the health system context; and (4) immunizing in the context of global interdependence. By 2010, all 50 countries planned to have introduced hepatitis B (HepB) vaccine, 48 the Haemophilus influenzae type B (Hib) vaccine and only a few countries had firm plans to introduce pneumococcal or rotavirus vaccines. Countries seem to be inadequately prepared in terms of cold-chain requirements to deal with the expected increases in storage that will be required for vaccines, and in making provisions to establish a corresponding surveillance system for planned new vaccine introductions. Immunization contacts are used to deliver other health interventions, especially in the countries in the World Health Organization (WHO) Africa Region. The cost for the planned immunization activities will double to U$27 per infant, of which U$5 per infant is the expected shortfall. Global Alliance for Vaccines and Immunization (GAVI) funding is becoming the largest contributor to immunization programmes.

http://heapol.oxfordjournals.org/content/28/1/11.abstract

The emergence of global attention to health systems strengthening

Health Policy and Planning
Volume 28 Issue 1 January 2013
http://heapol.oxfordjournals.org/content/current

Editor’s Choice: The emergence of global attention to health systems strengthening
Health Policy Plan. (2013) 28(1): 41-50 doi:10.1093/heapol/czs023
Tamara Hafner and Jeremy Shiffman
Free full text

Abstract
After a period of proliferation of disease-specific initiatives, over the past decade and especially since 2005 many organizations involved in global health have come to direct attention and resources to the issue of health systems strengthening. We explore how and why such attention emerged. A qualitative methodology, process-tracing, was used to construct a case history and analyse the factors shaping and inhibiting global political attention for health systems strengthening. We find that the critical factors behind the recent burst of attention include fears among global health actors that health systems problems threaten the achievement of the health-related Millennium Development Goals, concern about the adverse effects of global health initiatives on national health systems, and the realization among global health initiatives that weak health systems present bottlenecks to the achievement of their organizational objectives. While a variety of actors now embrace health systems strengthening, they do not constitute a cohesive policy community. Moreover, the concept of health systems strengthening remains vague and there is a weak evidence base for informing policies and programmes for strengthening health systems. There are several reasons to question the sustainability of the agenda. Among these are the global financial crisis, the history of pendulum swings in global health and the instrumental embrace of the issue by some actors.

http://heapol.oxfordjournals.org/content/28/1/41.abstract

Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction – Haryana State, India

Health Policy and Planning
Volume 28 Issue 1 January 2013
http://heapol.oxfordjournals.org/content/current

Original articles
Cost-effectiveness of Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization schedule in Haryana State, India
Madhu Gupta, Shankar Prinja, Rajesh Kumar, and Manmeet Kaur
Health Policy Plan. (2013) 28(1): 51-61 doi:10.1093/heapol/czs025

Abstract
Objective  In India, Haemophilus influenzae type b (Hib) vaccine introduction in the universal immunization programme requires evidence of its potential health impact and cost-effectiveness, as it is a costly vaccine. Since childhood mortality, vaccination coverage and health service utilization vary across states, the cost-effectiveness of introducing Hib vaccine was studied in Haryana state.

Methodology  A mathematical model was used to compare scenarios with and without Hib vaccination to estimate the cost-effectiveness of Hib vaccine in Haryana from 2010 to 2024. Demographic and National Family Health Surveys were used to estimate vaccination coverage and mortality rates among children under 5. Hib pneumonia, Hib meningitis and invasive Hib disease incidence were based on Indian studies. Vaccine and syringe prices of the UNICEF supply division were used. Cost-effectiveness from government and societal perspectives was calculated as the net incremental cost per unit of health benefit gained [disability-adjusted life years (DALYs) averted, life years saved, Hib cases averted, Hib deaths averted]. Sensitivity analysis was done using variation in parameter estimates among different states of India.

Findings  The incremental cost of Hib vaccine introduction from a government and a societal perspective was estimated to be US$81.4 and US$27.5 million, respectively, from 2010 to 2024. Vaccination of 73.3, 71.6 and 67.4 million children with first, second and third dose of pentavalent vaccine, respectively, would avert 7 067 817 cases, 31 331 deaths and 994 564 DALYs. Incremental cost per DALY averted from a government (US$819) and a societal perspective (US$277) was found to be less than the per capita gross national income of India in 2009. In sensitivity analysis, Hib vaccine introduction remained cost-effective for India.

Conclusion Hib vaccine introduction is a cost-effective strategy in India.

http://heapol.oxfordjournals.org/content/28/1/51.abstract

Editorial: Elimination of tropical disease through surveillance and response

Infectious Diseases of Poverty
2012, 1
http://www.idpjournal.com/content
[Accessed 12 January 2013]

Editorial  
Elimination of tropical disease through surveillance and response
Xiao-Nong Zhou, Robert Bergquist, Marcel Tanner
Infectious Diseases of Poverty 2013, 2:1 (3 January 2013)

Abstract (provisional)
Surveillance and response represent the final crucial steps in achieving effective control and particularly elimination of communicable diseases as recognized in the area of neglected tropical diseases (NTDs), applied in increasing numbers in endemic countries with ongoing control and elimination programmers. More and more national NTD elimination initiatives are scheduled based on the innovative and effective One world-One health perspective to detect pockets of transmission/disease reintroduction. Resource-constrained countries, which carry the heaviest NTD burdens, face various challenges how to strengthen the health system as well as developing effective and novel tools for surveillance and response tailored to local settings. Surveillance-response approaches take place in two different stages corralling the basic components of the surveillance-response system for NTD elimination. Six different research priorities have been identified:1) dynamic mapping of transmission; 2) near real-time capture of population dynamics; 3) modelling based on a minimum essential database/dataset; 4) implementation of mobile health (m-health) and sensitive diagnostics; 5) design of effective response packages tailored to different transmission settings and levels; and 6) validation of approaches and responses.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Effect of Narrative Reports about Vaccine Adverse Events

Medical Decision Making (MDM)
January 2013; 33 (1)
http://mdm.sagepub.com/content/current
Special Issue: Decision Aids and Risk Perception

Cornelia Betsch, Frank Renkewitz, and Niels Haase
Effect of Narrative Reports about Vaccine Adverse Events and Bias-Awareness Disclaimers on Vaccine Decisions: A Simulation of an Online Patient Social Network
Med Decis Making January 2013 33: 14-25, first published on August 8, 2012 doi:10.1177/0272989X12452342
http://mdm.sagepub.com/content/33/1/14.abstract

Abstract
Background.
As the number of individuals who search for health information in interactive online environments is increasing, patient networks deserve more scientific attention. Objective. To quantitatively examine if and how reading statistical and/or narrative information as typically displayed in patient networks (e.g., patientslikeme.com) affects decisions for pharmaceuticals. Previous work suggests that narrative information (e.g., about vaccine adverse events, VAE) affects risk perceptions and intentions. The authors compare the effect of narrative and statistical information about VAE on vaccination decisions and examine if a disclaimer reduces the narrative bias as well as if low numeracy leads to increased use of the narratives.

Method and Design.
In an online experiment, 458 participants were randomly assigned to a 3 (relative frequency of vaccine adverse events in 1, 7, or 17 of 20 cases) × 3 (type of information: narratives, summary statistics, or both) × 2 (bias awareness v. control disclaimer) between-subjects design.

Measurements.
Perceived risk, vaccination intention, and subjective numeracy.

Results.
A higher relative frequency of cases reporting VAE decreased the intention to get vaccinated. This relation was mediated by increased risk perception. The type of information moderated the contents’ impact: Summary statistics had the smallest impact, whereas narrative information was more influential, and the presence of both types of information had the greatest impact on risk perception. Individuals who received the bias-awareness disclaimer were less influenced by the patient network. Highly numerate individuals were generally more sensitive to the provided information independent of its format.

Conclusions.

Patient networks can influence vaccination decisions by delivering risk-related information. Disclaimers may help to reduce the influence if desired.

Reporting rates of adverse events following immunization: An international comparison of post-marketing surveillance programs with reference to China

Vaccine
Volume 31, Issue 4, Pages 567-724 (11 January 2013)
http://www.sciencedirect.com/science/journal/0264410X

Systematic review of reporting rates of adverse events following immunization: An international comparison of post-marketing surveillance programs with reference to China
Review Article
Pages 603-617
Biao Guo, Andrew Page, Huaqing Wang, Richard Taylor, Peter McIntyre

Abstract
Background
China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing a growing vaccine market mainly due to recent additions to the national immunization schedule, but data on post-marketing surveillance for adverse events following immunization (AEFI) are sparse.

Objectives
To compare reporting rates for various categories of AEFI from China with other routine post-marketing surveillance programs internationally.

Methods
Systematic review of published studies reporting rates of AEFI by vaccine, category of reaction and age from post-marketing surveillance systems in English and Chinese languages.

Results
Overall AEFI reporting rates (all vaccines, all ages) in Chinese studies were consistent with those from similar international studies elsewhere, but there was substantial heterogeneity in regional reporting rates in China (range 2.3–37.8/100,000 doses). The highest AEFI reporting rates were for diphtheria–tetanus–pertussis whole-cell (DTwP) and acellular (DTaP) vaccines (range 3.3–181.1/100,000 doses for DTwP; range 3.5–92.6/100,000 doses for DTaP), with higher median rates for DTwP than DTaP, and higher than expected rates for DTaP vaccine. Similar higher rates for DTwP and DTaP containing vaccines, and relatively lower rates for vaccines against hepatitis B virus, poliovirus, and Japanese encephalitis virus were found in China and elsewhere in the world.

Conclusions

Overall AEFI reporting rates in China were consistent with similar post-marketing surveillance systems in other countries. Sources of regional heterogeneity in AEFI reporting rates, and their relationships to differing vaccine manufacturers versus differing surveillance practices, require further exploration.

Sources of pertussis infection in young infants: A review of key evidence informing targeting of the cocoon strategy

Vaccine
Volume 31, Issue 4, Pages 567-724 (11 January 2013)
http://www.sciencedirect.com/science/journal/0264410X

Sources of pertussis infection in young infants: A review of key evidence informing targeting of the cocoon strategy
Review Article
Pages 618-625
K.E. Wiley, Y. Zuo, K.K. Macartney, P.B. McIntyre

Abstract
Background
The relative contribution of different categories of contact in transmitting pertussis to very young infants, who experience the most severe morbidity, is the most important single factor determining the likely benefit of pertussis vaccination of their close contacts (the “cocooning” strategy).

Objective
To identify, evaluate the quality of and summarise existing data on potential sources of infant pertussis infection in high income countries, focussing on infants under 6 months old.

Data sources:
Online databases MEDLINE and EMBASE. Additional studies were identified from the reference lists of relevant articles.

Study selection and analysis:
Study quality was evaluated by standardised criteria, based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. Pooled estimates of the proportion of pertussis cases attributable to various contact sources were calculated using data from the highest quality studies.

Results
Nine studies met the inclusion criteria; seven included data on contacts of hospitalised infants less than 6 months old. Case definitions and methods of contact ascertainment were variable. Most identified sources were from the household, of which 39% (95%CI 33–45%) were mothers, 16% (95%CI 12–21%) fathers, and 5% (95%CI 2–10%) grandparents. Estimates for siblings (16–43%) and non-household contacts (4–22%) were more heterogeneous. For 32–52% of infant cases, no source was identified. Asymptomatic pertussis infection was found in 8–13% of contacts evaluated.

Conclusions

These data suggest that the greatest potential impact of pertussis vaccination of adults to prevent severe disease in young infants comes from vaccinating mothers, followed by fathers, with grandparents having a minor role. Siblings varied in importance and, given recent data regarding waning immunity in vaccinated children, need further study. Non-household sources are also well documented, highlighting the potential limitations of the cocoon strategy to prevent severe infant disease.

Control of rubella and congenital rubella syndrome—A 40 year experience from Australia

Vaccine
Volume 31, Issue 4, Pages 567-724 (11 January 2013)
http://www.sciencedirect.com/science/journal/0264410X

Models of strategies for control of rubella and congenital rubella syndrome—A 40 year experience from Australia
Original Research Article
Pages 691-697
Zhanhai Gao, James G. Wood, Margaret A. Burgess, Robert I. Menzies, Peter B. McIntyre, C. Raina MacIntyre

Abstract
We investigated the impact of vaccination on rubella epidemiology in Australia, using a mathematical model fitted to Australian serosurvey data and incorporating pre-vaccination European estimates of rubella transmissibility. Mass infant measles–mumps–rubella (MMR) vaccination produced a 99% reduction in both rubella and congenital rubella syndrome (CRS) incidence by 2010 compared to the pre-vaccination era (1960–70). The model is consistent with reductions in CRS based on surveillance of congenital hearing impairment. Model simulations suggest that selective schoolgirl vaccination (1971–88) was associated with a 90% reduction in CRS incidence, but only a 1–4% reduction in rubella incidence. Our model predicted that these reductions in rubella were much less vulnerable to reductions in MMR vaccine coverage than for measles. In the future, a less than 15% decrease in MMR vaccine coverage is estimated to have minimal impact before 2060, but a 20% reduction may result in a 7-fold increase in rubella incidence, with the effective reproductive number R rising from 0.28 to 0.78 by 2060. The 99% reduction in both rubella and CRS incidence and low effective reproductive number (R ≤ 0.28) we documented after 2010 are consistent with Australia having achieved rubella elimination.

Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance

Adapting Group Sequential Methods to Observational Postlicensure Vaccine Safety Surveillance: Results of a Pentavalent Combination DTaP-IPV-Hib Vaccine Safety …

JC Nelson, O Yu, CP Dominguez-Islas, AJ Cook… – American Journal of …, 2013

Abstract To address gaps in traditional postlicensure vaccine safety surveillance and to
promote rapid signal identification, new prospective monitoring systems using large health-
care database cohorts have been developed. We newly adapted clinical trial group …

Implications of the Virginia Human Papillomavirus Vaccine Mandate for Parental Vaccine Acceptance

Qualitative Health Research
2012 Dec 28. [Epub ahead of print]
Margaret Jane Pitts and Kimberly Adams Tufts

Implications of the Virginia Human Papillomavirus Vaccine Mandate for Parental Vaccine Acceptance
Qual Health Res 1049732312470871, first published on December 28, 2012 as doi:10.1177/1049732312470871

Abstract
In 2009, Virginia became the first state in the United States to enact a school vaccine mandate for the human papillomavirus (HPV), putting it at the forefront of the national HPV vaccine mandate controversy. It is critical to explore the public response and sense making where the mandate has already been enacted. Thus, we conducted 8 focus group discussions among 33 Virginia parents to explore how they conceptualized the virus and vaccine and their responses to the mandate. Findings suggest that many parents are skeptical of and reluctant to follow a state-mandated vaccine requirement, choosing instead to opt out of the vaccine until they decide the time is right for their daughter and/or until they feel confident in their knowledge about the virus, vaccine, and the impetus for the mandate. Study results can inform future legislation among states considering HPV-related mandates and aid in the development of health-promotion materials within the context of a state mandate.

http://qhr.sagepub.com/content/early/2012/12/27/1049732312470871.abstract

Editorial – Pakistan’s victims – Muslim leaders should do more to support polio vaccines

Financial Times
http://www.ft.com
Accessed 12 January 2013

Editorial
January 11, 2013 6:42 pm

Pakistan’s victims – Muslim leaders should do more to support polio vaccines
Rarely has extremism become such an enemy of human health as in Pakistan. Alongside an escalating campaign of indiscriminate bombings, including the series of attacks that killed more than 100 people on Thursday, has been a steady trickle of targeted assassinations of immunisation workers engaged in efforts to beat polio. The Islamic world has to ensure the deaths are not in vain.

It is tempting to see the vaccine killings as a response to the CIA’s use of a hepatitis B programme as cover for its operation to track down Osama bin Laden in 2010. While few mourn the al-Qaeda leader, the grisly truth is that extremist groups have used this part of the story as a pretext to politicise vaccination and deter participants through violence.

It is difficult to prove a direct causal link, but previous western military actions and local ill-informed claims that vaccines are a covert sterilisation technique have helped to undermine programmes in several countries, notably in northern Nigeria, another residual outpost of polio.

In Pakistan, factors such as US drone attacks have been used to justify strikes against western targets extending beyond immunisers. Yet, the country’s use of “lady health workers” is particularly delicate: most communities prefer that women carry out the work. Extremists, however, are hostile to an active role for women on all counts.

It is tragic that vaccines should be wrongly perceived as western or Christian, let alone detrimental. The earliest records of immunisation are in China, India and the Ottoman Empire. Today many vaccines are manufactured in Asia.

It is understandable that public concern over the dangers of polio has fallen in direct proportion to the success of vaccination campaigns over the past 50 years in reducing the number of people affected. But outbreaks of other preventable diseases, such as measles, should serve as a reminder of the value of immunisation.

The Pakistani authorities need to take vaccination more seriously, with better funding, supervision, support and partnership with respected religious and secular leaders. Other Muslim governments and clerics should play a greater role in advocating and acting as mediators with religious groups in vaccine programmes around the world. Oil-rich countries in particular should become more active in funding.

Politicians should encourage “days of tranquility” of the type introduced during conflicts in Afghanistan and Sudan, with all sides benefiting from access to health workers. Finally, polio should become less of an exceptional campaign and be more integrated alongside other vaccination, health and social programmes. That would save costs and spread visible benefits for all regardless of their beliefs or social issues.

Opinion: The evolving role of the private sector in global health

The Huffington Post
http://www.huffingtonpost.com/
Accessed 12 January 2013

PINION:
8 January 2013
http://www.huffingtonpost.com/jeffrey-l-sturchio/the-evolving-role-health_b_2432823.html

Jeffrey L. Sturchio, Senior Partner, Rabin Martin [We work with multi-national corporations, non-profit and advocacy organizations, foundations, major universities, think tanks and government to help clients improve health and shape policy. We draw on diverse expertise to shape emerging issues with multidisciplinary strategies and programs.]
Co-authored with Dr. Adel Mahmoud, former president, Merck Vaccines

Lessons from India: How to promote the polio vaccine in Pakistan

New York Times
http://www.nytimes.com/
Accessed 12 January 2013.

Lessons from India: How to promote the polio vaccine in Pakistan
New York Times | 11 January 2013

Extract
“…What we did in India shows that by working hand-in-glove with the true faith leaders of the communities at risk — by gaining their trust and support through sincere dialogue and by keeping the focus always on the well-being of the child – polio eradication is achievable even under the most challenging conditions.”

By Ashok Mahajan, a member of the Rotary Club of Mulund, Maharashtra, is a Trustee of The Rotary Foundation of Rotary International, a spearheading partner in the Global Polio Eradication Initiative.

Twitter Watch (12 Janaury 2013 – 17:50)

Twitter Watch (12 Janaury 2013 – 17:50)
Items of interest from a variety of twitter feeds associated with immunization, vaccines and global public health. This capture is highly selective and is by no means intended to be exhaustive.

World Bank Data ‏@worldbankdata
Browse 250 #health, nutrition and population indicators for over 200 countries #opendata http://bit.ly/QaHb7W 
Retweeted by World Bank
9:30 AM – 11 Jan 13

CDC Flu ‏@CDCFlu
128 of 135 million total flu vax doses have been distributed. Vax may be hard to find. Try http://flushot.healthmap.org  or call your doc or pharmacy
Retweeted by CDCgov
12:40 PM – 11 Jan 13

PATH ‏@PATHtweets
Where there is no reliable clean water or electricity, a new test will make screening for #cervicalcancer possible. http://ow.ly/gK5fq 
12:50 PM – 11 Jan 13

GAVI Alliance ‏@GAVIAlliance
In 1st MOPAN review @GAVIAlliance is commended 4 effectiveness in increasing access 2 immunisation & focus on results! http://ht.ly/gJt1c 
7:34 AM – 11 Jan 13

Sabin Vaccine Inst. ‏@sabinvaccine
Did you know that our Sustainable Immunization Financing team works in 18 countries? Read more to find out which ones http://www.sabin.org/programs/vaccine-advocacy-education/sustainable-immunization-financing-sif …
9:28 AM – 10 Jan 13

GAVI Alliance ‏@GAVIAlliance

VIDEO: Great interview of @GAVIAlliance CEO, @GAVISeth, on Al Jazeera (8 January 2013): http://ht.ly/gHkS2  @AJEnglish

7:00 AM – 10 Jan 13 · Details

Vaccines: The Week in Review 5 January 2013

Editor’s Notes:

Email Summary: Vaccines: The Week in Review is available as a weekly email summary: please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

pdf version: A pdf of the current issues is available here: Vaccines_The Week in Review_5 January 2013_PDF

Twitter: Readers can also follow developments on twitter: @vaxethicspolicy.

Support: If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…

GPEI – Update: Polio this week – As of 04 January 2013 … Niger report polio

Update: Polio this week – As of 04 January 2013
Global Polio Eradication Initiative
http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx

[Editor’s Extract and bolded text]

– Niger reports polio: In the first outbreak of polio in 2012 outside of an endemic country or a country with re-established poliovirus, Niger has reported a case of wild poliovirus. This is the first case in the country since December 2011 and is related to virus originating in Nigeria.
– 2012 ends with fewest wild polio cases ever: The year ended with the fewest children paralyzed by wild polio virus, in the fewest places, in history. Two hundred and eighteen wild polio cases have been reported so far for 2012 – a greater than 60% reduction from 2011. Over the year, through the tireless dedication of the on-the-ground heroes of polio eradication, more than 2 billion doses of vaccine were distributed to 429 million children around the world.

Nigeria
– One new WPV case was reported in the past week (1 WPV1 from the Federal Capital Territory), bringing the total number of WPV cases for 2012 to 119. This is the most recent in the country and had onset of paralysis on 3 December. The area was covered in Sub-national Immunization Days on 18-21 December.
– No new circulating vaccine-derived poliovirus cases (cVDPV) were reported in the past week. – The total number of cVDPV cases for 2012 remains 4, with the most recent having onset of paralysis on 16 August.
– Given spread of WPV of Nigerian origin to Niger, targeted Supplementary Immunization Activities will take place in high-risk and under-served districts in Nigeria on 12-15 January, synchronized with Niger. National Immunization Days across Nigeria are planned for 2-5 February and 2-5 March.

Pakistan
– One new WPV case was reported in the past week, a WPV1 with onset of paralysis on 30 November in Khyber Pakhtunkhwa. The total number of WPV cases for 2012 is 58.
– Three new circulating vaccine-derived poliovirus (cVDPV) cases were reported in the past week, two from Balochistan and one from Sindh (Karachi area). The most recently reported case occurred in Sindh on 8 December and is related to the Balochistan outbreak. The total number of cVDPV cases for 2012 is now 15.
– Small-scale immunization activities are taking place on an ongoing basis in the polio-endemic areas of Pakistan, as the security situation allows.

Niger
– Niger reports polio: In the first outbreak of polio in 2012 outside of an endemic country or a country with re-established poliovirus, Niger has reported a case of wild poliovirus. This is the first case in the country since December 2011 and is related to virus originating in Nigeria.

West Africa
– One new WPV case was reported in the past week, a WPV1 from Tahoua province in Niger with onset of paralysis on 15 November. This is the first case in the region in 2012.

Decade of Vaccines Collaboration Secretariat Closes; WHO Exec Board to Review Global Vaccine Action Plan (GVAP)

   The Decade of Vaccines Collaboration announced that it ended secretariat operations as of 31 December 2012, noting that “the work of the Decade of Vaccines is continuing – carried out by the stakeholders that developed the GVAP.  The original plan was for the DoV Collaboration, including the secretariat, to dissolve or “sunset” at the end of 2012 so as not to create an additional structure. The countries, the regions and global health organizations will continue to carry out the vision of the GVAP at the country, regional and global levels.”
http://www.dovcollaboration.org/dov-collaboration-updates/december-2012-news-report/
The Weekly Epidemiological Record (WER) for 4 January 2013, vol. 88, 1 (pp 1–16) includes: Meeting of the Strategic Advisory Group of Experts on Immunization, November 2012 – conclusions and recommendations
http://www.who.int/entity/wer/2013/wer8801.pdf

[Editor’s Note: Below is an excerpt for the WER summary of the meeting’s GVAP agenda item]
Decade of Vaccines Global Vaccine Action Plan (GVAP)
“The session included an overview of progress in putting the GVAP into operation since the 65th World Health Assembly (WHA) in May 2012. Discussions have begun at the Regional level to update regional immunization plans in alignment with GVAP and to establish processes to monitor and report progress to the respective Regional Committees each year. The WHO and UNICEF guidance for preparation of national multi-year and annual plans for immunization are being updated to align them with the guiding principles and strategic objectives of GVAP and to foster greater alignment with national health sector plans.

‘The proposed structure and process for monitoring the implementation of the GVAP through a Monitoring & Evaluation /Accountability Framework was described. The framework has 3 elements: (i) monitoring results (based on the indicators for the GVAP Goals and Strategic Objectives); (ii) monitoring commitments and resources; and (iii) an independent review of progress.

Progress was described in the efforts to finalize monitoring indicators, establish operational definitions, sources of data, and the reporting process. SAGE was presented with the changes made to the indicators since its April 2012 meeting and the rationale for doing so, and was specifically asked for comments and recommendations.

“SAGE discussions mainly focused on:
(1) the feasibility and need for surveys to validate district level vaccine coverage measures; (2) adding an indicator of DTP3 coverage ≥80% for ≥3 years; (3) proposed indicators to measure “confidence in immunization”; (4) retention of indicator on district level DTP3 coverage; (5) choice of drop-out rate between the first dose of DTP and first dose of measles containing vaccine (MCV1) (DTP1-MCV1), or between the first and third dose of DTP vaccine (DTP1-DTP3); (6) addition of a surveillance indicator; (7) addition of an indicator to measure integration of immunization within health systems; and (8) addition of a vaccine price indicator…”
The WHO Executive Board will review an update to the GVAP at its 132nd session [EB132] in Geneva, 21–29 January 2013. The agenda item is listed as:
9. Communicable diseases
9.1 Global vaccine action plan
The supporting document – EB132/18 – is not yet posted.

Click to access B132_1-en.pdf

UNICEF announces tenders for pneumococcal conjugate, rotavirus and HPV vaccines for Middle Income Countries from 2013 to 2015

UNICEF announced tenders for pneumococcal conjugate, rotavirus and HPV vaccines for Middle Income Countries from 2013 to 2015 to assist with affordability, noting that “the disparity between the amounts Low Income and Middle Income Countries pay for the same vaccine can be significant.” Shanelle Hall, Director of UNICEF’s Supply Division, said, “The current market prices of new vaccines put these products out of reach for many countries whose economies have transitioned from ‘Low’ to ‘Middle’ Income over the last 20 years. This tender highlights work with the UN World Health Organization, industry, governments and partners to establish affordable, sustainable price levels for countries that are not eligible for international financial support to introduce these new and important life-saving vaccines.”

UNICEF said that for countries that wish to continue to purchase on their own, this tender “will improve pricing transparency by publishing reference price levels, product profiles and characteristics. This information will serve as the basis for negotiations between interested governments and manufacturers. The final price would be independently contracted.” Ms. Hall added that, “Making sure that children in Middle Income Countries have access to a new generation of life-saving supplies is critical. This tender builds on industry’s commitment to improved access and sustainable pricing consistent with the tenets of tiered pricing. Our goal is to help catalyse a more efficient and healthy market, which combined with increasing country commitment, will serve children in the decades to come,” she added.

The World Bank classifies a Middle Income Country as a country with a per capita Gross National Income between US$1,026 and US$12,475. Today, Middle Income Countries are home to 75 per cent of the world’s poor who live on less than US$2 a day. Middle Income governments that have so far expressed an indicative interest in the outcome of this tender include: Albania, Botswana, Cape Verde, Egypt, Gabon, Jordan, Lebanon, Moldova, Morocco, Namibia, the State of Palestine,  the Philippines, Sri Lanka, Swaziland, Syria, Tunisia and Turkmenistan. UNICEF is awaiting manufacturers’ responses and expects to begin issuing purchase orders on behalf of subscribing countries as early as June 2013. The Request for Proposal RFP-DAN-2012-501580 for Pneumococcal, Rotavirus and Human Papillomavirus Vaccines is available here: http://www.unicef.org/supply/index_66941.html. UNICEF’s strategy for vaccine procurement in Middle Income Countries is presented here: http://www.unicef.org/supply/index_66348.html

http://www.unicef.org/media/media_67112.html

UNICEF announces positive MOPAN assessment

UNICEF announced that the Multilateral Organization Performance Assessment Network (MOPAN) – a network of 17 donor countries that rate the effectiveness of multilateral organizations – published its most recent assessment of UNICEF, “finding that UNICEF had shown it was able to strengthen its effectiveness and to coordinate efforts to address key issues.” The latest assessment of UNICEF was led by the governments of Austria and Spain MOPAN assessments “provide an important snapshot of an organization’s management effectiveness from a strategic, operational, relationship and knowledge-based perspective. The assessment relies largely on perception-based surveys of in-country partners, peer organizations and donors. In 2012, country-level surveys were undertaken in Cambodia, the Democratic Republic of the Congo, Ghana, Honduras, Morocco, Niger, Nigeria, Philippines and Zimbabwe, serving as the basis of the 2012 report. UNICEF said it “welcomes the common MOPAN approach and the consultative process and is committed to follow up on the recommendations.”

31 December 2012  http://www.unicef.org/media/media_67100.html

Full MOPAN Reports on UNICEF:

http://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_1_Issued_December_2012.pdf

http://www.mopanonline.org/upload/documents/MOPAN_2012_UNICEF_Final_Vol_2_Issued_December_2012.pdf

Hopkins Bloomberg School wins four-year, $5 million grant from the Gates Foundation to promote the effective use of OCV

   The Johns Hopkins Bloomberg School of Public Health won a four-year, $5 million grant from the Bill & Melinda Gates Foundation to promote the effective use of oral cholera vaccine around the world. The Delivering Oral Vaccine Effectively (DOVE) program “will provide relief agencies and governments with technical assistance on how to use oral cholera vaccine, evaluate current vaccine-use practices and develop new field surveillance methods for monitoring and controlling outbreaks of the disease.” David Sack, MD, director of DOVE and professor in the Department of International Health at the Bloomberg School, said, “We believe this grant will greatly facilitate the appropriate use of the new cholera vaccine. In partnership with the World Health Organization, UNICEF and other national and international agencies, we believe the DOVE project will provide the knowledge, technical assistance and encouragement to bring this life-saving vaccine to those who need it most. In addition to researching and evaluating vaccine-use practices, DOVE “will establish cholera surveillance in the northern region of Cameroon near Lake Chad, which appears to be a cholera hotspot. The site will help researchers develop and study methods for detecting outbreaks in remote areas and potentially for using oral vaccine to contain the disease.”

http://www.eurekalert.org/pub_releases/2012-12/jhub-jhr122712.php

WHO – 2012 in review: key health issues

WHO – 2012 in review: key health issues
December 2012

Key public health milestones were reached in 2012, including the end of polio transmission in India and meeting the Millennium Development Goal target on drinking water ahead of schedule. Governments made important decisions on combating illicit trade in tobacco products, monitoring noncommunicable diseases, and conducting research on H5N1 influenza.

WHO supported response to a number of disease outbreaks, including Ebola in Uganda. The Organization encouraged countries to invest in testing, treating and tracking all cases of malaria, and to improve access to contraceptives. It issued guidance on the use of antiretroviral drugs to both prevent HIV transmission and keep people healthy.

WHO published new statistics highlighting the growing problem of high blood pressure and diabetes, (and) that 15 million babies are born preterm every year, but that overall progress on child survival is speeding up.

Other recommendations showed how to use weather information to protect public health, and how to ensure people with mental health conditions receive good care. World Health Day outlined ways to ensure healthy ageing, and the World Health Assembly adopted decisions on issues including nutrition, adolescent pregnancy, and the reform of WHO.

http://www.who.int/features/2012/year_review/en/index.html

Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons

Annals of Internal Medicine
1 January 2013, Vol. 158. No. 1
http://www.annals.org/content/current

Improved Immunogenicity With High-Dose Seasonal Influenza Vaccine in HIV-Infected Persons: A Single-Center, Parallel, Randomized Trial
Noah McKittrick, MD; Ian Frank, MD; Jeffrey M. Jacobson, MD; C. Jo White, MD; Deborah Kim, RPh; Rosemarie Kappes, RN, MPH; Carol DiGiorgio, RN; Thomas Kenney, BS; Jean Boyer, PhD; Pablo Tebas, MD; and for the Center for AIDS Research

Abstract
Background: HIV-infected persons have less robust antibody responses to influenza vaccines.

Objective: To compare the immunogenicity of high-dose influenza vaccine with that of standard dosing in HIV-positive participants.

Design: Randomized, double-blind, controlled trial. (ClinicalTrials.gov: NCT01262846)

Setting: The MacGregor Clinic of the Hospital of the University of Pennsylvania, Philadelphia, from 27 October 2010 to 27 March 2011.

Participants: HIV-infected persons older than 18 years.

Intervention: Participants were randomly assigned to receive either a standard dose (15 mcg of antigen per strain) or a high dose (60 mcg/strain) of the influenza trivalent vaccine.

Measurements: The primary end point was the rate of seroprotection, defined as antibody titers of 1:40 or greater on the hemagglutination inhibition assay 21 to 28 days after vaccination. The primary safety end point was frequency and intensity of adverse events. Secondary end points were seroconversion rate (defined as a greater than 4-fold increase in antibody titers) and the geometric mean antibody titer.

Results: 195 participants enrolled, and 190 completed the study (93 in the standard-dose group and 97 in the high-dose group). The seroprotection rates after vaccination were higher in the high-dose group for the H1N1 (96% vs. 87%; treatment difference, 9 percentage points [95% CI, 1 to 17 percentage points]; P = 0.029), H3N2 (96% vs. 92%; treatment difference, 3 percentage points [CI, −3 to 10 percentage points]; P = 0.32), and influenza B (91% vs. 80%; treatment difference, 11 percentage points [CI, 1 to 21 percentage points]; P = 0.030) strains. Both vaccines were well-tolerated, with myalgia (19%), malaise (14%), and local pain (10%) the most frequent adverse events.

Limitations: The effectiveness of the vaccine in preventing clinical influenza was not evaluated. The number of participants with CD4 counts less than 0.200 × 109 cells/L was limited.

Conclusion: HIV-infected persons reach higher levels of influenza seroprotection if vaccinated with the high-dose trivalent vaccine than with the standard-dose.

Primary Funding Source: National Institute of Allergy and Infectious Diseases and Center for AIDS Research of the University of Pennsylvania.

Addressing inequity to achieve the maternal and child health millennium development goals: looking beyond averages

BMC Public Health
(Accessed 5 January 2013)
http://www.biomedcentral.com/bmcpublichealth/content

Addressing inequity to achieve the maternal and child health millennium development goals: looking beyond averages
George M Ruhago, Frida N Ngalesoni, Ole F Norheim BMC Public Health 2012, 12:1119 (27 December 2012)

Abstract (provisional)
Background
Inequity in access to and use of child and maternal health interventions is impeding progress towards the maternal and child health Millennium Development Goals. This study explores the potential health gains and equity impact if a set of priority interventions for mothers and under fives were scaled up to reach national universal coverage targets for MDGs in Tanzania.

Methods
We used the Lives Saved Tool (LiST) to estimate potential reductions in maternal and child mortality and the number of lives saved across wealth quintiles and between rural and urban settings. High impact maternal and child health interventions were modelled for a five-year scale up, by linking intervention coverage, effectiveness and cause of mortality using data from Tanzania. Concentration curves were drawn and the concentration index estimated to measure the equity impact of the scale up.

Results
In the poorest population quintiles in Tanzania, the lives of more than twice as many mothers and under-fives were likely to be saved, compared to the richest quintile. Scaling up coverage to equal levels across quintiles would reduce inequality in maternal and child mortality from a pro rich concentration index of -0.11 (maternal) and -0.12 (children) to a more equitable concentration index of -0,03 and -0.03 respectively. In rural areas, there would likely be an eight times greater reduction in maternal deaths than in urban areas and a five times greater reduction in child deaths than in urban areas.

Conclusions
Scaling up priority maternal and child health interventions to equal levels would potentially save far more lives in the poorest populations, and would accelerate equitable progress towards maternal and child health MDGs.

The complete article is available as a provisional PDF. The fully formatted PDF and HTML versions are in production.

Risk of presentation to hospital with epileptic seizures after vaccination A/H1N1 2009 vaccine

British Medical Journal
05 January 2013 (Vol 346, Issue 7889)
http://www.bmj.com/content/346/7889

Risk of presentation to hospital with epileptic seizures after vaccination with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine (Pandemrix): self controlled case series study
BMJ 2013;345:e7594 (Published 28 December 2012)

Abstract – Open Access Article
Objective  To assess the risk of epileptic seizures in people with and without epilepsy after vaccination with a monovalent AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix; Glaxo SmithKline, Sweden).

Design  Register based self controlled case series.

Setting  Three Swedish counties (source population 750 000).

Participants 373 398 people (age 0-106, median 41.2) who were vaccinated. Vaccinated people with epileptic seizures, diagnosed as inpatients or outpatients, at any time from 90 days before until 90 days after any dose of vaccine.

Main outcome measures  Endpoints were admission to hospital or outpatient hospital care with epileptic seizures as the main diagnosis. The effect estimate of relative incidence was calculated as the incidence of epileptic seizures in period after exposure relative to the incidence of epileptic seizures in two control periods, one before and one after vaccination.

Results  859 people experienced epileptic seizures during the study period. There was no increased risk of seizures in people with previously diagnosed epilepsy (relative incidence 1.01, 95% confidence interval 0.74 to 1.39) and a non-significant decrease in risk for people without epilepsy (0.67, 0.27 to 1.65) during the day 1-7 risk period (where day 1 is the day of vaccination). In a second risk period (day 8-30), there was a non-significant increased risk of seizures in people without epilepsy (1.11, 0.73 to 1.70) but no increase in risk for those with epilepsy (1.00, 0.83 to 1.21).

Conclusions  This study found no evidence of an increase in risk of presentation to hospital with epileptic seizures after vaccination with a monovalent AS03 adjuvanted pandemic H1N1 influenza vaccine.

EDITORIAL: Universal health coverage anchored in the right to health

Bulletin of the World Health Organization
Volume 91, Number 1, January 2013, 1-80
http://www.who.int/bulletin/volumes/90/12/en/index.html

EDITORIALS
Universal health coverage anchored in the right to health
Gorik Ooms, Claire Brolan, Natalie Eggermont, Asbjørn Eide, Walter Flores, Lisa Forman, Eric A Friedman, Thomas Gebauer, Lawrence O Gostin, Peter S Hill, Sameera Hussain, Martin McKee, Moses Mulumba, Faraz Siddiqui, Devi Sridhar, Luc Van Leemput, Attiya Waris & Albrecht Jahn
doi: 10.2471/BLT.12.115808
Bulletin of the World Health Organization 2013;91:2-2A. doi: 10.2471/BLT.12.115808

European Commissioner for Development Andris Piebalgs recently pointed out the need for “updated and modernised [Millennium Development Goals], providing decent living standards for all – a set of minimum floors below which no one should fall”.1 He added that “these ‘MDGs plus’ would provide the basic rights that every citizen on the planet should expect … with, where necessary, for the poorest countries, the support of the international community through continued overseas development assistance”.1

We concur with Commissioner Piebalgs’ demand for basic rights for all people and feel that the right to health and its imperative of narrowing health inequities should be central to the post-2015 international health agenda. We take this stand as members of Go4Health, a consortium of academics and members of civil society tasked with advising the European Commission on the international health-related goals to follow the Millennium Development Goals (MDGs). What does this mean, given that the present MDGs on maternal health, child health and infectious disease control will probably be succeeded by the goal of universal health coverage, defined by the World Health Organization (WHO) as universal coverage with needed health services and financial risk protection?2,3

First, we view an aggregate health goal such as universal health coverage as an improvement over the current set of disparate goals. Ensuring the right to health requires a comprehensive approach. Universal health coverage anchored in the right to health, while building on efforts to meet the present health-related MDGs, would raise the bar for improving health care overall.

Second, although we support making universal health care one of the post-2015 development goals, we feel that universal health coverage is not enough, as defined by WHO and typically conceived,3 to ensure the right to health. For the right to health to become a reality, policy-makers must strive for a healthy physical and social environment (e.g. safe drinking water and good sanitation, adequate nutrition and housing, safe and healthy occupational and environmental conditions and gender equality.)4 These “underlying determinants of health” are partially captured in the present MDGs and their corresponding targets, although under different goals (e.g. nutrition under MDG 1, to eradicate extreme hunger and poverty, and water and sanitation under MDG 7, to promote environmental sustainability). These determinants and many more that are needed for a sustainable healthy environment should figure prominently in the post-2015 health agenda.

Third, specifying people’s entitlements is necessary but not enough. One important reason for the failure to attain all MDGs is the ambiguity of the “shared responsibility” mentioned in Article 2 of the Millennium Declaration: “We recognize that, in addition to our separate responsibilities to our individual societies, we have a collective responsibility to uphold the principles of human dignity, equality and equity at the global level.”5 If we want “every citizen on the planet” to claim his or her right to health, the post-2015 health agenda must specify how citizens will participate in the decision-making processes surrounding their health services and their physical and social environment. Furthermore, the agenda should also explicitly describe the accountability mechanisms that will make it possible for people to claim – not beg for – additional national public resources and international assistance, if needed.

Finally, we are concerned not just about the substance of the post-2015 health goals, but also about the process of formulating them. We have entered a post-2015 frenzy, as evidenced by the appointment of a high-level panel expected to submit a report to the United Nations Secretary-General in the first half of 2013.6 Go4Health is committed to ensuring that any post-2015 health development goals are articulated in collaboration with the communities whose health is at stake. However, truly participatory consultations take time and require a continuing relationship among researchers, governments and those communities. Such an approach should be adopted to prevent goals from being formulated by policy elites after token and superficial consultations, which would be at odds with the rights that must underpin the new goals.

References

– Piebalgs A. Achieving the MDGs and looking to the future. Luxembourg: European Commission; 2012. Available from: http://europa.eu/rapid/press-release_SPEECH-12-707_en.htm [accessed 30 November 2012].

– Evans DB, Marten R, Etienne C. Universal health coverage is a development issue. Lancet 2012; 380: 864-5 doi: 10.1016/S0140-6736(12)61483-4 pmid: 22959373.

– World Health Organization [Internet]. Positioning health in the post-2015 development agenda. Geneva: WHO; 2012. Available from: http://www.who.int/topics/millennium_development_goals/post2015/en/ [accessed 30 November 2012].

– General Comment No. 14. The right to the highest attainable standard of health. In: Twenty-second session, Committee on Economic, Social and Cultural Rights, Geneva, 25 April–12 May 2000 [Internet]. Geneva: CESCR; 2000 (E/C.12/2000/4). Available from: http://www2.ohchr.org/english/bodies/cescr/ [accessed 30 November 2012].

– Resolution 55/2. United Nations Millennium Declaration. In: Fifty-fifth United Nations General Assembly, New York, 5–8 September 2000 [Internet]. New York: United Nations; 2000 (A/RES/55/2). Available from: https://www.un.org/ga/55/ [accessed 30 November 2012].

– United Nations Secretary-General [Internet]. Secretary-General assembles high-level panel on post-2015 development agenda: appointing 26 members of government, civil society, private sector (press release). New York: Department of Public Information, News and Media Division; 31 July 2012. Available from: http://www.un.org/News/Press/docs/2012/sga1364.doc.htm [accessed 30 November 2012].

Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes

Bulletin of the World Health Organization
Volume 91, Number 1, January 2013, 1-80
http://www.who.int/bulletin/volumes/90/12/en/index.html

PERSPECTIVES
Vaccine Presentation and Packaging Advisory Group: a forum for reaching consensus on vaccine product attributes
Osman David Mansoor, Debra Kristensen, Andrew Meek, Simona Zipursky, Olga Popovaa, InderJit Sharma, Gisele Miranda, Jules Millogo & Heidi Lasher
doi: 10.2471/BLT.12.110700

“…Conclusion
The VPPAG is an important forum where stakeholders from the vaccine industry and immunization programmes interact to discuss in depth vaccine product characteristics and their impact on immunization programmes. Already, the VPPAG has brought about meaningful changes in the way vaccines are packaged and presented for developing country programmes. (The group’s 2008 terms of reference,18 current gPPP24 and a profile previously completed for the pneumococcal vaccine19 are available for download on WHO’s web site.)

The VPPAG could provide a model for organizations struggling to meet the needs of markets in both high- and low-income countries. Such organizations would benefit from feedback on product characteristics that could improve product applicability in markets with different infrastructures, and consumers in developing countries could benefit from access to a wider array of suitable products without unnecessary delay. Having a forum that allows constructive dialogue between the public and private sector furthers our shared goal of preventing disease, disability and death from vaccine-preventable diseases by designing products that can more easily reach those who will most benefit from immunization.”

Improving UN Funding to Strengthen Global Health Governance: Amending the Helms – Biden Agreement

Global Health Governance
Volume VI, Issue 1: Fall 2012
– December 31, 2012
http://blogs.shu.edu/ghg/2012/12/31/volume-vi-issue-1-fall-2012/

Improving United Nations Funding to Strengthen Global Health Governance- Amending the Helms – Biden Agreement
Timothy K. Mackey and Thomas E. Novotny

Abstract
Global health governance is widely considered fragmented after more than a decade of inconsistent support for multi-lateral organizations and faced with the emergence of many new global health donors and non-state enterprises. This paper addresses a series of events marked by enactment of the Helms-Biden agreement in 1999. This legislation ensured that United States funding for the United Nations was to be conditional upon reforms and reductions of U.S. assessments. Although passage of the legislation allowed its largest contributor/debtor to pay back arrears and continue payments going forward, it also represented a growing trend in U.S. unilateralism and disengagement from support for multi-national organizations. In particular, continued arrears and budgetary restrictions have affected specialized U.N. agencies such as the World Health Organization. This agency has experienced a zero nominal growth budget that may have impacted its governance capacity. We review the potential impact of the Helms-Biden legislation on WHO governance, and suggest that the governance of this important global health agency may benefit from its timely repeal.